10-Q: Annexon Q2 2025: Losses Widen Amid R&D Surge

Annexon, Inc. reported a significant increase in net losses and R&D expenses in Q2 2025, driven by advanced clinical trials, while projecting its cash runway into Q4 2026 and signaling a need for substantial future financing.

Summary

• Net loss for Q2 2025 increased to $49.2 million, up 66% from $29.6 million in Q2 2024.
• Research and development (R&D) expenses surged by 76% to $44.2 million in Q2 2025, primarily due to the Phase 3 ARCHER II trial and tanruprubart FORWARD study.
• Contract manufacturing expenses for tanruprubart and vonaprument increased significantly, up 132% for the quarter and over 200% for the six months ended June 30, 2025.
• Cash and cash equivalents, along with short-term investments, totaled $227.0 million as of June 30, 2025, down from $312.0 million at December 31, 2024.
• Existing capital resources are projected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2026, but substantial additional financing will be required thereafter.
• Enrollment for the global Phase 3 ARCHER II trial for vonaprument in Geographic Atrophy (GA) was completed in July 2025, with topline data expected in H2 2026.
• A Marketing Authorization Application (MAA) submission for tanruprubart in Guillain-Barré Syndrome (GBS) in Europe is anticipated in Q1 2026.
• Common warrants to purchase 6.9 million shares were amended in June 2025, extending their term to June 30, 2026, and removing the cashless exercise option, potentially yielding $39.9 million if exercised for cash.

Sentiment

Score: 4

Explanation: While the company is making notable clinical progress with its pipeline, including completing enrollment for a pivotal Phase 3 trial and securing key regulatory designations, its financial performance shows a concerning trend of rapidly increasing net losses and cash burn. The explicit need for "substantial additional financing" in the near future indicates a high risk of further shareholder dilution, outweighing the positive clinical developments in the short to medium term.

Positives

• Completed enrollment of 659 patients in the global Phase 3 ARCHER II trial for vonaprument in Geographic Atrophy (GA) in July 2025, a significant clinical milestone.
• Established a global registration path with the FDA and EMA for vonaprument, supporting its potential as the first approved treatment for vision protection in dry AMD with GA in both regions.
• Vonaprument received Priority Medicine (PRIME) designation from the EMA and was selected for the EMA's Product Development Coordinator (PDC) Pilot, indicating strong regulatory support.
• Tanruprubart (ANX005) for Guillain-Barré Syndrome (GBS) has consistently demonstrated rapid and sustained functional improvements in completed placebo-controlled Phase 3 and proof-of-concept studies.
• Tanruprubart has been granted Fast Track and Orphan Drug designation by the FDA, and Orphan designation by the EMA, which could expedite development and provide market exclusivity.
• The ANX1502 oral small molecule program showed general tolerability and supportive impact on a pharmacodynamic biomarker in Phase 1, with an ongoing POC study in Cold Agglutinin Disease (CAD).
• Amended common warrants could provide approximately $39.9 million in gross proceeds if exercised for cash by June 30, 2026.

Negatives

• Net loss significantly increased to $49.2 million for Q2 2025, up 66% from $29.6 million in Q2 2024, and to $103.5 million for the six months ended June 30, 2025, up 89% from $54.8 million in the prior year period.
• Research and development (R&D) expenses surged by 76% for the quarter and 101% for the six-month period, indicating a rapid increase in cash burn.
• Total cash and short-term investments decreased by approximately $85 million from $312.0 million at December 31, 2024, to $227.0 million at June 30, 2025, reflecting significant cash usage.
• Net cash used in operating activities for the six months ended June 30, 2025, was $88.1 million, a substantial increase from $50.0 million in the same period of 2024.
• Interest and other income, net, decreased by 35% for the quarter and 24% for the six-month period due to lower average cash and investment balances.
• The company has an accumulated deficit of $814.2 million as of June 30, 2025, and has incurred losses since inception, with no products approved for sale or revenue generated from product sales.
• The 2021 At-the-Market (ATM) Program, which generated $38.4 million in net proceeds in H1 2024, expired on August 15, 2024, removing a potential source of capital.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, making future viability difficult to assess.
• Substantial additional financing will be required beyond the projected cash runway into Q4 2026; failure to obtain this capital could force delays, reductions, or termination of product development programs and commercialization efforts.
• Biopharmaceutical product development is inherently risky, with no assurance that any product candidates will receive regulatory approval.
• The company may encounter substantial delays in clinical trials or may not be able to conduct or complete them on expected timelines.
• Data from clinical trials conducted outside the United States may not be accepted by the FDA or comparable foreign regulatory authorities, potentially requiring additional trials.
• Adverse events or undesirable side effects from product candidates could halt clinical development, delay or prevent regulatory approval, or limit commercial potential.
• Reliance on third-party suppliers for manufacturing poses risks, including loss of suppliers or their failure to comply with regulatory requirements or provide sufficient quantities.
• Successful commercialization depends on adequate coverage, reimbursement levels, and pricing policies from governmental authorities and health insurers, which may be difficult to obtain.
• Any future collaboration arrangements may not be successful, adversely affecting development and commercialization.
• Inability to obtain, maintain, and enforce intellectual property protection could allow competitors to market similar products.
• The company's stock price has been and could remain volatile.
• Actual or perceived failure to comply with data protection laws could lead to enforcement actions, litigation, or adverse publicity.
• The company must prioritize development, potentially expending resources on candidates that do not yield successful products.
• Conducting a global Phase 3 program for vonaprument (ARCHER II) is expensive and time-consuming, and additional capital may be needed.
• Results of operations may fluctuate significantly due to various factors, making future results difficult to predict.
• Public health crises could adversely affect preclinical and clinical trials.
• The novel C1q inhibition approach may cause unforeseen safety events in larger patient populations.
• Difficulties enrolling patients in clinical trials could cause delays.
• Interim, top-line, and preliminary data may change as more data become available.
• Even if approved, product candidates may fail to achieve broad physician and patient adoption.
• Orphan Drug designation benefits, including market exclusivity, may not be maintained.
• Breakthrough Therapy, Fast Track, or PRIME designations do not guarantee faster development or approval.
• Disruptions at regulatory agencies could hinder timely approval.
• Small molecule product candidates, if developed, could face generic competition.
• Business operations are subject to healthcare regulatory laws, which could expose the company to penalties.
• The company needs to increase its organization size and may experience difficulties managing growth.
• Failure to attract and retain senior management and key scientific personnel could adversely affect the business.
• Product liability lawsuits could result in substantial liabilities.
• Use of hazardous materials requires compliance with environmental laws, which can be expensive.
• Cybersecurity risks and failure to maintain IT system security could lead to adverse consequences.
• Changes in tax laws and regulations may have an adverse effect.
• International trade policies, including tariffs, may adversely affect the business.
• Natural disasters could adversely affect operations.
• Provisions in charter documents and Delaware law could discourage a takeover.
• Claims for indemnification by directors and officers may reduce available funds.
• Exclusive forum for disputes could limit stockholders' ability to obtain a favorable judicial forum.
• No current intention to pay dividends; return on investment depends on stock price appreciation.
• Ability to use net operating loss carryforwards and other tax attributes may be limited.
• Sales of a substantial number of shares could cause stock price to fall.

Future Outlook

Management projects existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the fourth quarter of 2026. Substantial additional financing will be required beyond that point. The company expects to continue incurring losses and negative cash flows from operations for at least the next several years. Plans include advancing tanruprubart towards global registration with an MAA submission in Europe expected in Q1 2026, and reporting topline data for the ARCHER II Phase 3 trial in H2 2026. An update on ANX1502 PK/PD learnings from CAD patients is anticipated by the end of 2025.

Management Comments

• "Based on projected activities, management projects that existing cash and cash equivalents and short-term investments will enable the Company to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements."
• "Management expects to continue to incur losses and negative cash flows from operations for at least the next several years."
• "We continue to engage with applicable EU and U.S. regulators to advance tanruprubart towards registration worldwide."
• "We are in ongoing dialogue with the FDA to gain clarity on the generalizability package to support a BLA submission."
• "We have established a global registration path with the FDA and EMA which supports the potential of vonaprument to be the first treatment approved in both Europe and the U.S. for the protection of vision in patients who have dry AMD with GA, assuming positive Phase 3 results."
• "We anticipate that PK/PD learnings from CAD patients will inform application of ANX1502 in a broad array of other autoimmune indications, and we plan to provide an update by the end of 2025."

Industry Context

Annexon operates in the highly competitive biopharmaceutical industry, specializing in novel therapies for classical complement-mediated neuroinflammatory diseases. Its approach targets C1q, the initiating molecule of the classical complement pathway, which is a novel therapeutic strategy. The company is developing treatments for rare and debilitating conditions like Guillain-Barré Syndrome (GBS), for which there are currently no FDA-approved therapies, and Geographic Atrophy (GA), a leading cause of blindness with no approved therapies specifically targeting vision preservation. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles, with a strong emphasis on proprietary therapeutics and intense competition from larger, more established pharmaceutical and biotechnology companies.

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings at this time.

Related Party Transactions

• An entity related to one of the company's directors participated in the December 2023 public offering, purchasing 350,000 shares of common stock for approximately $1.0 million.
• The June 2025 amendment to common warrants included a related party transaction involving 613,497 common warrants held by a member of the board of directors, which accounted for $0.2 million of the deemed dividend recognized.

Stakeholder Impact

• Shareholders face potential for significant dilution due to the explicit need for "substantial additional financing" and the availability of the ATM program, coupled with increased losses and cash burn.
• Employees may benefit from increased headcount and stock-based compensation, but the company's financial health could impact future compensation and job security.
• Patients with Guillain-Barré Syndrome (GBS), Geographic Atrophy (GA), and other autoimmune conditions could potentially benefit from new therapies if product candidates receive regulatory approval.
• Creditors may face increased risk due to the company's rapidly increasing accumulated deficit and ongoing negative cash flows, although the current cash runway extends into Q4 2026.
• Suppliers and contractors are likely to see continued business due to increased research and development and manufacturing activities, but their financial stability could be impacted by the company's need for future financing.

Next Steps

• Continue engagement with EU and U.S. regulators for tanruprubart registration.
• Submit Marketing Authorization Application (MAA) for tanruprubart in Europe in Q1 2026.
• Report topline data for ARCHER II Phase 3 trial in H2 2026.
• Provide an update on ANX1502 PK/PD learnings from Cold Agglutinin Disease (CAD) patients by the end of 2025.
• Seek additional funding in the future through public or private equity offerings, debt financings, credit/loan facilities, or collaborations.
• Continue to advance product candidates through late-stage clinical trials.
• Invest in capabilities to prepare for commercialization, including manufacturing.
• Hire additional personnel to support the organization.
• Expand insurance coverage to include the sale of any approved product candidates.

Key Dates

Recommendation

While Annexon is making notable clinical progress with its pipeline, including completing enrollment for a pivotal Phase 3 trial and securing key regulatory designations, the financial results indicate a rapidly deteriorating cash position and widening losses. The company's explicit need for "substantial additional financing" in the near future presents a significant risk of further shareholder dilution. For a seasoned investor, the promising pipeline offers long-term potential, but the current financial trajectory and the inherent risks of clinical development warrant a cautious "Hold" stance rather than a "Buy" or "Sell," pending clearer financial stability or more definitive clinical outcomes.

Keywords

Biopharmaceutical, Neuroinflammatory diseases, Classical complement pathway, C1q inhibition, Guillain-Barré Syndrome, GBS, Tanruprubart, ANX005, Geographic Atrophy, GA, Vonaprument, ANX007, Autoimmune diseases, ANX1502, Clinical trials, Phase 3, Orphan Drug, Fast Track, PRIME designation, SEC filing, 10-Q, Biotech, Drug development, Clinical stage